Liquid Biopsies, Are We Ready for Prime Time?

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2023 Feb 16

PMID 36796879

Authors

Nicola Normanno

Kathi Apostolidis

Mark Stewart

Affiliations

Soon will be listed here.

Citing Articles

Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee.

Monette A, Warren S, Barrett J, Garnett-Benson C, Schalper K, Taube J J Immunother Cancer. 2024; 12(7).

PMID: 39032943 PMC: 11261685. DOI: 10.1136/jitc-2024-009427.

Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma.

Soleimani M, Thi M, Janfaza S, Ozcan G, Mazurek S, Ozgun G Sci Rep. 2024; 14(1):8603.

PMID: 38615118 PMC: 11016103. DOI: 10.1038/s41598-024-59337-4.

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine.

Bao Y, Zhang D, Guo H, Ma W Cancer Sci. 2024; 115(4):1060-1072.

PMID: 38308498 PMC: 11007055. DOI: 10.1111/cas.16097.

References

Deans Z, Williams H, Dequeker E, Keppens C, Normanno N, Schuuring E . Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers' survey. Virchows Arch. 2017; 471(6):809-813. PMC: 5711978. DOI: 10.1007/s00428-017-2222-z. View

Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W . Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020; 10(12):1842-1853. PMC: 8358981. DOI: 10.1158/2159-8290.CD-20-0047. View

Normanno N, Maiello M, Chicchinelli N, Iannaccone A, Esposito C, De Cecio R . Targeting the EGFR T790M mutation in non-small-cell lung cancer. Expert Opin Ther Targets. 2016; 21(2):159-165. DOI: 10.1080/14728222.2017.1272582. View

Fairley J, Cheetham M, Patton S, Rouleau E, Denis M, Dequeker E . Results of a worldwide external quality assessment of cfDNA testing in lung Cancer. BMC Cancer. 2022; 22(1):759. PMC: 9275131. DOI: 10.1186/s12885-022-09849-x. View

Normanno N, Apostolidis K, De Lorenzo F, Beer P, Henderson R, Sullivan R . Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. Semin Cancer Biol. 2021; 84:293-301. DOI: 10.1016/j.semcancer.2021.08.002. View

Zavala V, Bracci P, Carethers J, Carvajal-Carmona L, Coggins N, Cruz-Correa M . Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer. 2020; 124(2):315-332. PMC: 7852513. DOI: 10.1038/s41416-020-01038-6. View

Normanno N, Apostolidis K, Wolf A, Al Dieri R, Deans Z, Fairley J . Access and quality of biomarker testing for precision oncology in Europe. Eur J Cancer. 2022; 176:70-77. DOI: 10.1016/j.ejca.2022.09.005. View

Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S . Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study. EBioMedicine. 2020; 57:102861. PMC: 7334809. DOI: 10.1016/j.ebiom.2020.102861. View

Jamshidi A, Liu M, Klein E, Venn O, Hubbell E, Beausang J . Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell. 2022; 40(12):1537-1549.e12. DOI: 10.1016/j.ccell.2022.10.022. View

10.

Qiu B, Guo W, Zhang F, Lv F, Ji Y, Peng Y . Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 2021; 12(1):6770. PMC: 8605017. DOI: 10.1038/s41467-021-27022-z. View

11.

Li X, Dowling E, Yan G, Dereli Z, Bozorgui B, Imanirad P . Precision Combination Therapies Based on Recurrent Oncogenic Coalterations. Cancer Discov. 2022; 12(6):1542-1559. PMC: 9524464. DOI: 10.1158/2159-8290.CD-21-0832. View

12.

Pascual J, Attard G, Bidard F, Curigliano G, De Mattos-Arruda L, Diehn M . ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022; 33(8):750-768. DOI: 10.1016/j.annonc.2022.05.520. View

13.

Tie J, Cohen J, Lahouel K, Lo S, Wang Y, Kosmider S . Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022; 386(24):2261-2272. PMC: 9701133. DOI: 10.1056/NEJMoa2200075. View

14.

Vellanki P, Ghosh S, Pathak A, Fusco M, Bloomquist E, Tang S . Regulatory implications of ctDNA in immuno-oncology for solid tumors. J Immunother Cancer. 2023; 11(2). PMC: 9936292. DOI: 10.1136/jitc-2022-005344. View

15.

Moding E, Nabet B, Alizadeh A, Diehn M . Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. Cancer Discov. 2021; 11(12):2968-2986. PMC: 8976700. DOI: 10.1158/2159-8290.CD-21-0634. View

16.

Mok T, Wu Y, Lee J, Yu C, Sriuranpong V, Sandoval-Tan J . Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin Cancer Res. 2015; 21(14):3196-203. DOI: 10.1158/1078-0432.CCR-14-2594. View